Mahamaya Lifesciences Ltd
Audited Financial Results along with Auditors Report for the half year and financial Year ended on 31st March, 2026
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 25 May 2026, 01:39 PM IST · BSE ID: e57a7ed6-d511-4574-ae0c-ccd6f5459f4c
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its annual financial results for the past year, showing its income and profit performance.
🤖 AI Summary
- Mahamaya Lifesciences Limited approved Audited Consolidated Financial Results for the year ended March 31, 2026.
- Consolidated Net Profit for FY26 reached INR 1,652.33 Lakhs, up from INR 1,281.16 Lakhs in FY25.
- Consolidated Revenue from Operations for FY26 stood at INR 32,887.30 Lakhs, compared to INR 26,414.86 Lakhs in FY25.
- The Group includes subsidiary Mahamaya Lifesciences (FZE) incorporated in UAE.
- The company was incorporated in 2002 and recently listed on BSE SME, limiting historical public data.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue From Operations (Year Ended 31-Mar-26)
32,887.30 Lakhs
24.58
Consolidated Net Profit for the Period (Year Ended 31-Mar-26)
1,652.33 Lakhs
28.97
Basic Earnings Per Equity Share (Year Ended 31-Mar-26)
8.33
10.77
Total Shareholder's fund (March 31, 2026)
12,192.99 Lakhs
🏢 How This Affects the Company
The company's consolidated revenue from operations increased to INR 32,887.30 Lakhs in FY26, indicating growth in its core business activities.
Consolidated Net Profit for FY26 grew to INR 1,652.33 Lakhs. Total assets increased to INR 13,308.23 Lakhs, and shareholder's funds increased to INR 12,192.99 Lakhs.
The auditor noted that the consolidated financial results include un-audited management certified financial results of subsidiary Mahamaya Lifesciences (FZE).
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, with FY26 consolidated net profit per share at 8.33 basic and diluted earnings.
🔍
Management Signal
The approval of both standalone and consolidated financial results signals management's adherence to regulatory disclosure requirements for a public listed entity.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Next quarterly results — evaluate growth trajectory for FY27.
Updates on subsidiary auditing practices — verify resolution of un-audited status.
Any further disclosures regarding operational expansion or strategy.
MEDIUM RISK
The inclusion of un-audited subsidiary financials introduces a level of reporting risk.
💡 Investor Takeaway
Mahamaya Lifesciences Limited reported Audited Consolidated Net Profit of INR 1,652.33 Lakhs for the financial year ended March 31, 2026, marking a 28.97% increase from INR 1,281.16 Lakhs in FY25. Revenue from Operations grew by 24.58% to INR 32,887.30 Lakhs.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated Net Profit for FY26 increased to INR 1,652.33 Lakhs from INR 1,281.16 Lakhs in FY25, a 28.97% YoY growth.
- Revenue from Operations for FY26 rose to INR 32,887.30 Lakhs from INR 26,414.86 Lakhs in FY25, reflecting 24.58% YoY growth.
⚠️ Concerns
- The consolidated financial results include un-audited management certified results for subsidiary Mahamaya Lifesciences (FZE).
- Basic and Diluted Earnings Per Equity Share decreased to 3.72 for H2 FY26 from 4.71 in H1 FY26.
📅 Company Track Record
Mahamaya Lifesciences Limited (formerly Mahamaya Lifesciences Pvt. Ltd.) was incorporated in 2002. The company recently listed on BSE SME, which means limited historical public financial data is available for extended comparisons. This is one of the early full annual disclosures post-listing.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Mahamaya Lifesciences Limited's consolidated net profit for FY26?
Mahamaya Lifesciences Limited reported a consolidated net profit of INR 1,652.33 Lakhs for the financial year ended March 31, 2026.
What was the consolidated revenue from operations for Mahamaya Lifesciences Limited in FY26?
The consolidated revenue from operations for Mahamaya Lifesciences Limited stood at INR 32,887.30 Lakhs for the financial year ended March 31, 2026.
Which subsidiary is included in Mahamaya Lifesciences Limited's consolidated results?
The consolidated financial results include the subsidiary M/s. Mahamaya Lifesciences (FZE), which is incorporated in the UAE.
Were the subsidiary financials audited in the consolidated results?
The consolidated financial results include un-audited management certified financial results of the subsidiary Mahamaya Lifesciences (FZE).
What were the basic earnings per equity share for Mahamaya Lifesciences Limited for FY26?
Basic Earnings Per Equity Share for Mahamaya Lifesciences Limited was 8.33 for the financial year ended March 31, 2026.
Questions based on this BSE filing only. For information purposes.